Arcellx (ACLX) Equity Average (2021 - 2025)
Arcellx's quarterly Equity Average came in at $421.6 million in Q4 2025, down 10.1% year-on-year from $468.9 million in Q4 2024, and up 1.22% quarter-over-quarter from $416.5 million in Q3 2025.
Arcellx has reported Equity Average for 5 years, with the latest figure at $421.6 million in Q4 2025.
- For the quarter ending Q4 2025, Equity Average fell 10.1% year-over-year to $421.6 million; the trailing twelve-month figure through Dec 2025 stood at $421.6 million (down 10.1% YoY), and the FY2025 full-year result was $428.6 million, down 8.83% from the prior year.
- Equity Average for Q4 2025 stood at $421.6 million, up from $416.5 million in the prior quarter.
- The five-year high for Equity Average was $491.9 million in Q2 2024, with the low at -$112.7 million in Q4 2021.
- Average Equity Average over 5 years is $260.7 million, with a median of $298.7 million recorded in 2023.
- Year-over-year, Equity Average jumped 2298.68% in 2023 and decreased 17.75% in 2025.
- Tracing ACLX's Equity Average over 5 years: stood at -$112.7 million in 2021, then soared by 113.91% to $15.7 million in 2022, then jumped by 2298.68% to $375.8 million in 2023, then advanced by 24.79% to $468.9 million in 2024, then fell by 10.1% to $421.6 million in 2025.
- The last three Equity Average figures came in at $421.6 million (Q4 2025), $416.5 million (Q3 2025), and $404.6 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 421.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 421.56 Mn |
| Sep 30, 2025 | 416.50 Mn |
| Jun 30, 2025 | 404.56 Mn |
| Mar 31, 2025 | 435.85 Mn |
| Dec 31, 2024 | 468.91 Mn |
| Sep 30, 2024 | 485.09 Mn |
| Jun 30, 2024 | 491.87 Mn |
| Mar 31, 2024 | 490.98 Mn |
| Dec 31, 2023 | 375.75 Mn |
| Sep 30, 2023 | 279.90 Mn |
| Jun 30, 2023 | 298.69 Mn |
| Mar 31, 2023 | 49.38 Mn |
| Dec 31, 2022 | 15.67 Mn |
| Sep 30, 2022 | 279.95 Mn |
| Jun 30, 2022 | 275.78 Mn |
| Mar 31, 2022 | 53.21 Mn |
| Dec 31, 2021 | -112.66 Mn |
| Sep 30, 2021 | -96.27 Mn |
| Jun 30, 2021 | -81.49 Mn |